title: Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection.
authors.affiliation: Humanitas Cancer Center, Istituto Clinico Humanitas, Istituto Di Ricovero e Cura a Carattere Scientifico, Rozzano, Italy.
authors.forename: Maria Chiara
authors.initials: MC
authors.lastname: Tronconi
authors.forename: Francesco
authors.initials: F
authors.lastname: Sclafani
authors.forename: Lorenza
authors.initials: L
authors.lastname: Rimassa
authors.forename: Carlo
authors.initials: C
authors.lastname: Carnaghi
authors.forename: Nicola
authors.initials: N
authors.lastname: Personeni
authors.forename: Armando
authors.initials: A
authors.lastname: Santoro
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068818:Cetuximab; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D017809:Fatal Outcome; D005838:Genotype; D006801:Humans; D007262:Infusions, Intravenous; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D018579:Patient Selection; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D012307:Risk Factors; D018631:ras Proteins / Q000235:genetics
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077146:Irinotecan; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068818:Cetuximab; D002166:Camptothecin